While this happened, Maxim Group upgraded its Annovis Bio Inc [ANVS] rating to a Buy from a a Hold in a research note published recently. A number of analysts have revised their coverage, including Canaccord Genuity’s analysts, who began to cover the stock in late December with a ‘”a Buy”‘ rating. Maxim Group also remained covering ANVS and reiterated its “Buy” recommendation on July 07, 2021.
Price Performance Review of ANVS
On Tuesday, Annovis Bio Inc [NYSE:ANVS] saw its stock fall -5.61% to $5.05. Over the last five days, the stock has lost -0.59%. Annovis Bio Inc shares have risen nearly 0.40% since the year began. Nevertheless, the stocks have fallen -58.78% over the past one year. While a 52-week high of $20.00 was reached on 01/03/25, a 52-week low of $4.21 was recorded on 01/07/25. SMA at 50 days reached $6.61, while 200 days put it at $8.27.
Levels Of Support And Resistance For ANVS Stock
The 24-hour chart illustrates a support level at 4.69, which if violated will result in even more drops to 4.33. On the upside, there is a resistance level at 5.49. A further resistance level may holdings at 5.93. The Relative Strength Index (RSI) on the 14-day chart is 41.14, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.30, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 39.57%. Stochastics %K at 75.78% indicates the stock is a holding.
How much short interest is there in Annovis Bio Inc?
A steep rise in short interest was recorded in Annovis Bio Inc stocks on 2024-12-13, growing by 0.17 million shares to a total of 1.56 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-15 was 1.39 million shares. There was a rise of 10.78%, which implies that there is a positive sentiment for the stock.
